Tofacitinib oral sustained release dosage forms
US9937181B2 · kind B2 · utility
3Cited by
12References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 14, 2014 |
| Grant date | Apr 10, 2018 |
| Priority date | — |
| Expiry date | Mar 14, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.